Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871098 | 0.90 | FNTA (0.49) | BCHEFNTAFNTBLTB4R2DRD2 | |
| SCHEMBL629682 | 0.83 | FNTA (0.69) | BCHEFNTAFNTBLTB4R2 | |
| SCHEMBL7869054 | 0.83 | FNTA (0.45) | FNTAFNTBLTB4R2L3MBTL1 | |
| SCHEMBL6626881 | 0.81 | FNTA (0.77) | FNTAFNTB | |
| SCHEMBL6626875 | 0.81 | FNTA (0.77) | FNTAFNTB | |
| SCHEMBL7870287 | 0.77 | AGTR1 (0.44) | FNTAFNTBLTB4R2 | |
| SCHEMBL630063 | 0.77 | MYC (0.49) | FNTAFNTBLTB4R2 | |
| SCHEMBL7870123 | 0.77 | FNTA (0.41) | FNTAFNTBLTB4R2LPAR1BRS3 | |
| SCHEMBL6627185 | 0.74 | FNTA (0.83) | FNTAFNTB | |
| SCHEMBL6627187 | 0.74 | FNTA (0.83) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |